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sis of the CSF showed neoplastic cells with a frequency 
of 92.0% (Fig. 2C) and positivity for both CD56 and CD123 
on immunocytochemical staining (Fig. 2D). He was diag-
nosed with leptomeningeal involvement of BPDCN. He was 
treated with intrathecal injections of high-dose cytarabine 
(40 mg) and methotrexate (15 mg) for 3 months, and he 
has been in complete remission for 4 months without evi-
dence of residual disease.
DISCUSSION
Because markers are useful for confirming BPDCN, a 
recently performed multicenter study recommends im-
munohistochemical staining using 6 antigens, such as CD4 
(positive in 94.6% of cases), CD56 (positive in 96.5% of 
cases), CD123 (positive in 95.3% of cases), TCL1 (positive 
in 89.3% of cases), CD2AP (positive in 80.5% of cases), 
and BDCA2/CD303 (positive in 75.0% of cases) [1]. As a 
single antigen does not exhibit positivity in all cases of 
BPDCN, immunohistochemical staining using at least the 
3 antigens mentioned previously (CD4, CD56, and CD123), 
all of which possess higher positivity rates compared with 
other antigens, should be performed to confirm BPDCN 
to provide maximum sensitivity. Our 2 cases demonstrated 
positivity for all these 3 antigens, which is adequate evidence 
of BPDCN involvement. Given that leptomeningeal involve-
ment in BPDCN is a rare phenomenon, our second patient, 
who developed simultaneous leukemic manifestation and 
leptomeningeal involvement of BPDCN, is a very rare case 
and worth being reported.
In conclusion, we report 2 cases of BPDCN exhibiting 
leukemic manifestation (1 with simultaneous lepto-
meningeal involvement) confirmed with positive CD4, 
CD56, and CD123 expression on immunohistochemical 
staining and flow cytometry. Immunohistochemical staining 
for CD4, CD56, and CD123 can confirm the BPDCN diag-
nosis, and it should be performed in all cases suspected 
of having BM involvement in BPDCN.
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Bone marrow hypoplasia, 
isochromosome 8q and deletion of 
chromosome 6q preceding B-cell 
lymphoma
TO THE EDITOR:  Abnormalities of chromosome 6q involv-
ing deletion of the regions 6q16-q27 have been reported 
in a variety of hematologic malignancies, most frequently 
in multiple myeloma [1-3]. The 8q isochromosome is also 
an uncommon clonal abnormality found primarily in T-pro-
lymphocytic leukemia [4, 5]. Concurrent chromosome 6q- 
and i(8) are extremely rare in patients with hematologic 
malignancies and have never been reported as chromosomal 
abnormalities preceding evidence of malignancy.
Several case reports suggested that chromosomal abnor-
malities can provide evidence for hematologic malignancies 
before they develop [1-3]. We describe a patient with bone 
marrow hypoplasia and persistent unexplained chromoso-
mal abnormalities of del(6)(q16) and i(8)(q10) who sub-
sequently developed B-cell lymphoma 8 months after his 
initial presentation.
CASE
A 50-year-old man was admitted to our hospital in 
December 2009 with persistent fever. Peripheral blood 
counts showed hemoglobin 9.0 g/dL, white blood cell (WBC) 
count 6.2×109/L (65% neutrophils, 15% lymphocytes, 10% 
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Fig. 1. Initial bone marrow biopsy showed (A) aplastic marrow 
(hematoxylin and eosin stain, ×100). In August 2010, repeat 
biopsy showed (B) increased cellularity with abnormal lymphoid 
infiltration that was (C) positive for CD20 on immunohisto-
chemical stain (×100).
Fig. 2. Giemsa-banded karyotype showing 46,XY,del(6)(q16),i(8)(q10) 
9 months before evidence of B-cell lymphoma in the bone marrow. The 
abnormal chromosomes are marked by arrows.
monocytes, 8% atypical lymphocytes, 2% eosinophils), and 
platelets 201×109/L. The reticulocyte count, iron, folate, and 
vitamin B12 levels were within the normal range.
The bone marrow showed a 1.2:1 myeloid:erythroid (M:E) 
ratio, no evident dysplasia and decreased cellularity (20%) 
(Fig. 1A). Cytogenetic analysis performed on bone marrow 
using a 24-hour unstimulated culture revealed the following 
distinct abnormal clone: 46,XY,del(6)(q16),i(8)(q10)[8]/46, 
XY[12] (Fig. 2). To evaluate his fever of unknown origin, 
brain magnetic resonance imaging (MRI), whole-body posi-
tron emission tomography/computerized tomography (PET/ 
CT) and thoracic and abdominal CT were performed. These 
studies revealed only moderate hepatosplenomegaly with 
no evidence of malignancy. In addition, markers for viral 
infection and autoimmune disease showed negative results.
In August 2010, peripheral blood counts showed hemoglo-
bin 9.1 g/dL, WBC count 4.45×109/L (73% neutrophils, 11% 
lymphocytes, 9% monocytes, 6% atypical lymphocytes, 1% 
eosinophils), and platelets 154×109/L. The bone marrow 
showed 1.7:1 M:E ratio, no evident infiltration of abnormal 
lymphoid cells, and hypocellular marrow. However, bone 
marrow biopsy showed relatively increased cellularity (40–
60%) than before, with focal infiltration of atypical lym-
phoid cells that were positive for CD20 and CD79a, but 
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negative for CD3, myeloperoxidase (MPO) and terminal 
deoxynucleotidyl transferase (TdT) on immunohistochem-
ical stain (Fig. 1B and 1C). The results of chromosomal 
analysis were 46,XY,del(6)(q16),i(8)(q10)[7]/46,XY[5], show-
ing the same abnormal clone as 8 months previously. Repeat 
brain MRI showed focal enhancements in the frontal and 
parietal skull bones suggestive of hematologic malignancy 
such as lymphoma or myeloma. Repeat whole-body PET/CT 
showed increased patchy uptake in multiple levels of the 
thoracic and lumbar spine suspicious of bone marrow 
infiltration. Cerebrospinal fluid analysis showed many atyp-
ical lymphoid cells. Together, these findings were consistent 
with lymphoma involving the central nervous system (CNS) 
and the patient was diagnosed as having B-cell lymphoma 
confined to the bone marrow and CNS (stage IV).
There were no accessible lymph nodes to perform a diag-
nostic biopsy. Treatment was immediately initiated with 
cyclophosphamide, doxorubicin, vincristine, and pre-
dnisone (CHOP). Bone marrow analysis showed complete 
hematologic remission after 2 cycles of CHOP and the bone 
marrow karyotype after chemotherapy was normal 
(46,XY[20]). In May 2011, he underwent autologous periph-
eral blood stem cell transplantation (PBSCT). Two years 
after PBSCT, in October 2013, the patient showed no mor-
phologic evidence of residual lymphoma and no suspicious 
findings on follow-up whole-body PET/CT.
DISCUSSION
Deletion of 6q is frequently described in lymphoid 
malignancies. In lymphoid malignancies, a range of deleted 
sub-regions has been identified within the chromosomal 
region 6q14-q21. Interestingly, the most proximal region 
has been identified in adult T-cell leukemia, whereas the 
more distal regions have been linked to childhood B-ALL 
and, rarely, chronic lymphocytic leukemia [6]. The detection 
of a 6q deletion in several malignancies suggests that this 
region contains an unidentified tumor-suppressor gene that 
deserves further investigation of its role in the malignant 
process [7]. Del(6q) has been shown to be a prognostic 
factor associated with longer event-free survival in adult 
T-ALL [5]. In our case, the patient had a favorable clinical 
course without relapse during 4 years of follow-up, even 
with CNS involvement. Accordingly, this case supports an 
association between del(6q) and favorable prognosis.
There have been 182 cases of i(8)(q10) in hematologic 
malignancies published, with the majority (166 cases, 91.2%) 
exhibiting complex karyotypes [5], suggesting that i(8)(q10) 
is a secondary chromosomal abnormality. However, reports 
of i(8)(q10) in acute B-cell lymphoblastic leukemia/lympho-
ma have rarely been reported with only 5 cases published 
to date [5]. Several reports have suggested that the gain 
of 8q, but not the loss of 8p, is important in leukemogenesis 
[4, 8].
It can be difficult to distinguish bone marrow hypoplasia 
preceding lymphoma from aplastic anemia. In our case, 
persistent anemia and bone marrow hypoplasia were prom-
inent, although neutropenia or thrombocytopenia was not 
evident. In adults, the major causes of pancytopenia involv-
ing bone marrow are clonal disorders such as acute myeloid 
leukemia (26%), myelodysplastic syndrome (17%) and non- 
Hodgkin lymphoma (NHL, 6%) [9]. In this case, persistent 
bone marrow hypoplasia was suspected as a rare manifes-
tation of NHL. The most likely cause for the patient’s bone 
marrow hypoplasia was a clonal disorder that suppressed 
hematopoietic stem cell proliferation and eventually re-
sulted in lymphoma by selection of an abnormal clone [10, 
11]. We suspected that the patient had lymphoma at the 
initial presentation, with the aplastic phase caused by the 
clonal cells’ direct inhibition of normal bone marrow stem 
cells.
Hematologic malignancies preceded by chromosomal ab-
normalities have rarely been reported [1, 3]. However, in 
these cases the preceding chromosomal abnormalities may 
have signaled disease progression rather than the hemato-
logic malignancy itself. This report describes the first case 
of B-cell lymphoma preceded by bone marrow hypoplasia 
with del(6)(q16) and i(8)(q10) prior to morphologic evidence 
of hematologic malignancy, followed by a favorable and 
persistent complete remission for nearly 4 years from the 
initial detection of the chromosomal abnormalities. Close 
follow-up in patients with abnormal karyotypes, even with-
out morphologic evidence of hematologic malignancy, could 
uncover hidden hematologic malignancies and allow ini-
tiation of early and proper treatment.
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T-cell large granular lymphocytic 
leukemia: 4 cases
 
TO THE EDITOR: T-cell large granular lymphocytic leuke-
mia (T-LGL) is a rare clonal hematological disorder charac-
terized by peripheral blood and bone marrow lymphocytic 
infiltration with large granular lymphocytes (LGLs), spleno-
megaly, and cytopenia, of which neutropenia is most com-
mon [1]. T-LGL is characterized by persistent increases in 
LGLs ranging from 2×109/L to 20×109/L on peripheral blood 
in the absence of a reactive cause [2]. The exact pathogenesis 
is unknown, but is believed to result from clonal expansion 
of mature postthymic T cells [3]. T-LGL typically presents 
in the sixth decade of life, with an equal male to female 
ratio [4]. Approximately 40% of patients have an associated 
autoimmune disorder, most commonly rheumatoid arthritis 
(RA), pure red cell aplasia, or immune thrombocytopenia 
[5]. Approximately one third of patients are asymptomatic 
when routine blood counts reveal cytopenia and LGL, which 
leads to diagnosis. The symptoms, if present, are related 
to cytopenia [6].
Bone marrow aspirate may be required to confirm the 
diagnosis, especially in those with low absolute numbers 
of circulating LGLs. Patients with T-LGL have a median 
survival of more than 10 years [7]. The most common in-
dications for treatment are cytopenia, recurrent infection, 
pure red cell aplasia, progressive splenomegaly, and B symp-
toms [8]. The reported incidence of T-LGL is 2–5% of the 
chronic lymphoproliferative disorders (LPDs) in North 
America and about 6% in Asia [9]. The incidence and preva-
lence is not known in Pakistan. In this case series, we de-
scribe the laboratory findings and clinical courses of 4 pa-
tients diagnosed with T-LGL in a tertiary care hospital.
CASES
The first case was a 24-year-old man who presented with 
lymphocytosis in November 2010. His physical examination 
was unremarkable and showed no hepatosplenomegaly or 
lymphadenopathy. A complete blood cell (CBC) count re-
vealed lymphocytosis with the presence of LGLs (Table 
1). Based on bone marrow morphological and im-
munophenotypic assessments, the patient was diagnosed 
with T-LGL (Table 1). His follow-up visits showed persistent 
lymphocytosis with a declining platelet count. On his fol-
low-up in December 2013, CBC revealed hemoglobin (Hb), 
13.5 g/dL; white blood cell (WBC) count, 17.9×109/L with 
an absolute lymphocyte count (ALC) of 11.4×109/L; and 
platelets, 93×109/L.
The second case was a 61-year-old man who was referred 
in November 2010 for assessment of persistent lymphocy-
tosis lasting for about 7 months. His physical examination 
was unremarkable. CBC showed lymphocytosis, whereas 
blood smear, bone marrow morphology, and immuno-
phenotyping were consistent with T-LGL (Table 1). He re-
mained asymptomatic throughout the disease course with-
out any treatment. His CBC in August 2013 revealed Hb, 
14 g/dL; WBC, 7.6×109/L with an ALC of 5.3×109/L; and 
platelets, 100×109/L.
The third case was a 61-year-old man who was diagnosed 
with hairy cell leukemia (HCL) in 1992 after morphological 
findings from peripheral smear/bone marrow and under-
went splenectomy as the sole treatment for HCL. He was 
then lost to follow-up until 1998, when he presented with 
recurrent chest infections. His physical examination was 
unremarkable, whereas CBC revealed lymphocytosis and 
LGLs on peripheral smear (Table 1). Subsequent examination 
of bone marrow morphology and immunophenotyping was 
consistent with T-LGL (Table 1). During follow-up visits, 
he continued to have chest infections and was started on 
low-dose oral methotrexate 5 mg once daily for 7 days 
in a 4-week cycle. He responded well to treatment and 
the repeated infections resolved. He is still on the regimen 
and is asymptomatic. His most recent follow-up CBC re-
vealed Hb, 12.5 g/dL; WBC, 19.5×109/L with an ALC of 
12×109/L; and platelets, 181×109/L.
